EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma

Lukuan You, Yinmei Xu, Yankan Fu, Jianxiong Li

PeerJ · 2026

DOI: 10.7717/peerj.20618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2026. Verfasst von Lukuan You und 3 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Polo-Like Kinase 1, Gene Expression Regulation, Neoplastic, Biomarkers, Tumor. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PLK1 is associated with various malignant tumors, but its correlation with lung adenocarcinoma (LUAD) remains unclear. This research seeks to explore the differences in PLK1 expression in LUAD and evaluate the relationship between PLK1 expression and the outcomes for LUAD patients.

Methods

Information on LUAD patients was sourced from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx). The XianTao Academic Online Platform was employed for systematic analysis of PLK1, including: (1) Wilcoxon rank-sum test to compare PLK1 expression between LUAD and normal tissues; (2) logistic regression analysis evaluating PLK1-clinicopathological feature relationships; (3) Kaplan–Meier and COX regression analyses assessing prognostic significance; (4) nomogram construction for survival prediction. Immunohistochemical (IHC) staining results from the Human Protein Atlas (HPA) validated PLK1 protein expression. Functional characterization using the XianTao platform included: (1) Analysis of PLK1-coexpressed genes using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways; (2) single-sample gene set enrichment analysis (ssGSEA) to measure immune cell infiltration in tumors with high PLK1 expression. In vitro validation included: (1) cell proliferation assessment (CCK-8 and colony formation assays); (2) apoptosis detection via Annexin V/PI staining; (3) cell cycle analysis by PI staining flow cytometry; (4) cell cycle-related protein expression evaluation using Western blotting (Cyclin B1, CDK1).

Results

PLK1 expression was significantly elevated in LUAD tumor tissues compared to adjacent normal samples across multiple cohorts. Elevated PLK1 expression was strongly associated with advanced clinicopathological stages (tumor/node/metastasis (T/N/M)) and poorer overall survival. Functional enrichment analysis revealed that genes co-expressed with PLK1 were predominantly involved in cell cycle regulatory pathways. Furthermore, transcriptomic profiling indicated a significant correlation between high PLK1 expression and an immunosuppressive tumor microenvironment. Experimental validation in A549 cells demonstrated that pharmacological inhibition of PLK1 ( via GSK461364 ) effectively suppressed cell proliferation, induced G2/M phase arrest, promoted apoptosis, and led to the accumulation of Cyclin B1 and CDK1 proteins.

Conclusion

PLK1 overexpression signifies aggressive disease and poor prognosis in LUAD, mechanistically linked to cell cycle dysregulation and an immunosuppressive microenvironment. Our findings nominate PLK1 as a promising therapeutic target and biomarker, warranting further investigation into PLK1-directed therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsPolo-Like Kinase 1Gene Expression Regulation, NeoplasticBiomarkers, TumorAdenocarcinoma of LungDatabases, GeneticLogistic ModelsKaplan-Meier EstimateProportional Hazards ModelsPrognosisNomogramsImmunohistochemistryCell ProliferationApoptosisCell CyclePredictive Value of TestsHumansMaleFemaleMiddle AgedAgedCell Line, Tumor

Stichwörter der Autor:innen

Cell cycleImmune infiltrationLUADPLK1Prognosis

Substanzen

PLK1 protein, humanPolo-Like Kinase 1Biomarkers, Tumor

Autor:innen und Institutionen

  • Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
  • Chinese PLA General Hospital (PLA Medical School), Beijing, China.

Zitieren

APA

You, L., Xu, Y., Fu, Y., & Li, J. (2026). PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma. PeerJ. https://doi.org/10.7717/peerj.20618

Vancouver

You L, Xu Y, Fu Y, Li J. PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma. PeerJ. 2026. doi:10.7717/peerj.20618

BibTeX
@article{You2026,
  author = {You, Lukuan and Xu, Yinmei and Fu, Yankan and Li, Jianxiong},
  title = {PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma},
  journal = {PeerJ},
  year = {2026},
  doi = {10.7717/peerj.20618}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche